Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | HTR1B | P28222 | 17/20 | 1.00 |
| ▸ | HTR1D | P28221 | 16/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | HTR1E | P28566 | 2/20 | 0.67 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004976 | 0.90 | HTR1F (0.81) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7011904 | 0.90 | HTR1F (0.81) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7014483 | 0.90 | HTR1F (0.81) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL30909071 | 0.90 | HTR1F (0.81) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL30909108 | 0.90 | HTR1F (0.81) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7008621 | 0.87 | HTR1F (0.77) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7009292 | 0.87 | HTR1F (0.77) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7015518 | 0.86 | HTR1F (0.75) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7011661 | 0.85 | HTR1F (0.73) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL7008481 | 0.84 | HTR1A (1.00) | HTR1FHTR1AHTR1BHTR1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0842934-B1 | 5-HT1F agonists | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1082958-A2 | 5-HT1F agonists in chronic pain | ELI LILLY AND COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| US-5998622-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5919936-A | 5-HT1F AGONIST INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5817671-A | ANTISEROTONIN AGENT; ANALGESICS; MIGRAINE THERAPY; COMPOUND CONTAINING PYRROLO(3,2-B)PYRIDINE RING | ELI LILLY AND COMPANY (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0842934-A1 | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885HTR1A 2/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.